EntryPoint Capital LLC Has $377,000 Stock Holdings in Quanterix Co. (NASDAQ:QTRX)

EntryPoint Capital LLC increased its position in shares of Quanterix Co. (NASDAQ:QTRX) by 117.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,504 shares of the company’s stock after buying an additional 19,203 shares during the quarter. EntryPoint Capital LLC owned about 0.09% of Quanterix worth $377,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in shares of Quanterix during the fourth quarter valued at approximately $66,000. Peapack Gladstone Financial Corp bought a new stake in Quanterix during the 3rd quarter valued at $131,000. Levin Capital Strategies L.P. acquired a new position in Quanterix during the fourth quarter worth $159,000. Tallon Kerry Patrick bought a new position in shares of Quanterix in the fourth quarter valued at $169,000. Finally, Intech Investment Management LLC acquired a new position in shares of Quanterix during the third quarter valued at about $170,000. Institutional investors own 86.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Scotiabank restated an “outperform” rating on shares of Quanterix in a report on Tuesday. Canaccord Genuity Group lowered their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th.

Quanterix Price Performance

Shares of QTRX stock opened at $6.66 on Thursday. Quanterix Co. has a one year low of $6.30 and a one year high of $23.94. The company has a market cap of $258.25 million, a P/E ratio of -6.28 and a beta of 1.33. The firm has a 50-day moving average of $8.08 and a 200-day moving average of $10.72.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The firm had revenue of $35.16 million during the quarter, compared to analysts’ expectations of $34.93 million. As a group, research analysts expect that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.